Chinese Firms At JPM Not About China, It’s Time To Go Global
From Specialized Biotech To Global Biopharma In Decade
Executive Summary
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.
You may also be interested in...
China Reins In Cancer Drug Trials, Stressing Patient Needs and Benefits
China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.
China’s Regulator Has New Head But Will He Advance Further Reforms?
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.